Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

Vir Biotechnology VIR is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement. Analysts estimate that Vir ...

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.48 per share a year ago. These ...

Dr Rajesh Gupta, vice president, global health portfolio and public-private partnerships at Vir Biotechnology, said: “COVID-19 reinforced the ever-present global threat of infectious diseases ...

The analysis below examines the analyst ratings and average 1-year price targets of Ardelyx, Vir Biotechnology and CareDx, three significant industry players, providing valuable insights into ...

PI, a global leader in precision motion control and nanopositioning, announces fast delivery of its nanometer-precise, high-speed V-308 vertical nanopositioning stage. The system offers 7 mm of ...